Does transcatheter aortic valve replacement reduce all-cause mortality or disabling stroke in low-risk patients with aortic stenosis compared to surgical aortic valve replacement?
In low-risk patients with aortic stenosis, TAVR demonstrates durable benefits compared to surgery for the composite of all-cause mortality or disabling stroke at 3 years.
Within the Evolut Low Risk study, TAVR at 3 years showed durable benefits compared with surgery with respect to all-cause mortality or disabling stroke. (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients; NCT02701283).
Forrest et al. (Sun,) studied this question.